Literature DB >> 21351861

Role of fixed combinations in the management of open-angle glaucoma.

Anton Hommer1.   

Abstract

The first-line option for lowering intraocular pressure (IOP) is a single hypotensive agent, but patients frequently require additional IOP-lowering agents to reach their target pressures. Disadvantages of this multi-therapy approach include washout effect, inconvenience and poor adherence. Fixed combinations (FCs) combine two or more hypotensive agents in a single bottle, providing a convenient once-daily therapy, which tends to improve adherence. FCs generally offer equivalent efficacy to concomitant use of the individual components, with equivalent or superior tolerability. Studies also show that FCs can be more cost effective than nonfixed combinations. In terms of optimizing IOP control, minimizing visual field deterioration, preventing visual disability and minimizing associated healthcare costs, FCs are an important component of glaucoma management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21351861     DOI: 10.1586/erp.10.83

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

1.  Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece.

Authors:  Tryfon G Rotsos; Vasso G Kliafa; Kevin J Asher; Dimitrios Papaconstantinou
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

Review 2.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

3.  Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.

Authors:  M Francesca Cordeiro; Ivan Goldberg; Rhett Schiffman; Paula Bernstein; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2015-08-31

4.  Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.

Authors:  Arturo Alezzandrini; Douglas Hubatsch; Rene Alfaro
Journal:  Adv Ther       Date:  2014-08-20       Impact factor: 3.845

Review 5.  How ocular surface disease impacts the glaucoma treatment outcome.

Authors:  Snježana Kaštelan; Martina Tomić; Kata Metež Soldo; Jasminka Salopek-Rabatić
Journal:  Biomed Res Int       Date:  2013-10-09       Impact factor: 3.411

Review 6.  Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus.

Authors:  Quang H Nguyen
Journal:  Patient Prefer Adherence       Date:  2014-06-12       Impact factor: 2.711

Review 7.  Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future.

Authors:  Anastasios G Konstas; Leopold Schmetterer; Andreas Katsanos; Cindy M L Hutnik; Gábor Holló; Luciano Quaranta; Miguel A Teus; Hannu Uusitalo; Norbert Pfeiffer; L Jay Katz
Journal:  Adv Ther       Date:  2020-10-27       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.